Home

MICHAEL JOHN TOMSICEK

CIK 1570392 · Chief Financial Officer · last filed 2026-06-22

MICHAEL JOHN TOMSICEK is a Chief Financial Officer who has filed 42 SEC Form 4 insider transactions across 8 companies since 2013. The most recent filing, for ACRV, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$5.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $131.2K across reported positions. 17 SEC filings were submitted jointly with CUBIST PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$131.2K

Companies

8

Total Filings

42

Lifetime Open-Market Net

-$5.65M

Filer Profile

Reported Address
28 OVERLOOK DRIVE
BEDFORD, MA 01730
Related Filers
CUBIST PHARMACEUTICALS INC — 17 joint filings, latest 2015-01-21
ABIOMED INC — 6 joint filings, latest 2017-07-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACRV Director 9,366 $2.00 $18.7K $0 5 2026-06-22
MIST Director 15,000 $0.98 $14.7K $79.8K 8 2026-06-12
CRSP Chief Financial Officer 1,891 $51.72 $97.8K -$5.61M 10 2021-08-10
CRISPR Therapeutics AG (PZRX) Delisted Chief Financial Officer — — — $0 1 2017-11-14
ABIOMED INC (ABMD) Delisted Vice President, CFO 27,081 $381.02 $10.32M $0 3 2017-07-18
ABIOMED INC (APOL) Delisted Vice President, CFO 26,800 — — $0 2 2016-05-26
CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted SVP & Chief Financial Officer 0 — — -$67.7K 6 2015-01-21
CUBIST PHARMACEUTICALS INC (CBST) Delisted SVP & Chief Financial Officer 3,318 — — -$49.6K 7 2013-10-02

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-22 ACRV Grant (A) — $0 EDGAR
2026-06-12 MIST Grant (A) — $0 EDGAR
2026-05-20 ACRV Grant (A) +9,366 $0 EDGAR
2025-06-17 ACRV Grant (A) — $0 EDGAR
2025-06-12 MIST Grant (A) — $0 EDGAR
2024-08-29 MIST Grant (A) — $0 EDGAR
2024-06-24 ACRV Grant (A) — $0 EDGAR
2023-06-09 MIST Grant (A) — $0 EDGAR
2022-11-16 ACRV Grant (A) — $0 EDGAR
2022-10-21 MIST Buy (P) +15,000 $79.8K EDGAR
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.